148 related articles for article (PubMed ID: 9839588)
1. p53 and p53-regulated genes in bladder cancer.
Keegan PE; Lunec J; Neal DE
Br J Urol; 1998 Nov; 82(5):710-20. PubMed ID: 9839588
[No Abstract] [Full Text] [Related]
2. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
[TBL] [Abstract][Full Text] [Related]
3. Induction of apoptosis by p53, bax, bcl-2, and p21 expressed in colorectal cancer.
Katsumata K; Sumi T; Tomioka H; Aoki T; Koyanagi Y
Int J Clin Oncol; 2003 Dec; 8(6):352-6. PubMed ID: 14663636
[TBL] [Abstract][Full Text] [Related]
4. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
Droller MJ
J Urol; 2001 May; 165(5):1811-2. PubMed ID: 11345951
[No Abstract] [Full Text] [Related]
5. bcl-2/bax expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical chemotherapy after resection.
Ye D; Li H; Qian S; Sun Y; Zheng J; Ma Y
J Urol; 1998 Dec; 160(6 Pt 1):2025-8; discussion 2029. PubMed ID: 9817315
[TBL] [Abstract][Full Text] [Related]
6. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
[TBL] [Abstract][Full Text] [Related]
7. Aberrant p21 regulation in radioresistant primary glioblastoma multiforme cells bearing wild-type p53.
Kraus A; Gross MW; Knuechel R; Münkel K; Neff F; Schlegel J
J Neurosurg; 2000 Nov; 93(5):863-72. PubMed ID: 11059670
[TBL] [Abstract][Full Text] [Related]
8. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
9. Altered patterns of MDM2 and TP53 expression in human bladder cancer.
Lianes P; Orlow I; Zhang ZF; Oliva MR; Sarkis AS; Reuter VE; Cordon-Cardo C
J Natl Cancer Inst; 1994 Sep; 86(17):1325-30. PubMed ID: 8064890
[TBL] [Abstract][Full Text] [Related]
10. TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus.
Skomedal H; Kristensen GB; Nesland JM; Børresen-Dale AL; Tropé C; Holm R
J Pathol; 1999 Apr; 187(5):556-62. PubMed ID: 10398121
[TBL] [Abstract][Full Text] [Related]
11. p53 and MDM2 in the development and progression of bladder cancer.
Schmitz-Dräger BJ; Kushima M; Goebell P; Jax TW; Gerharz CD; Bültel H; Schulz WA; Ebert T; Ackermann R
Eur Urol; 1997; 32(4):487-93. PubMed ID: 9412812
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival.
Hernandez I; Maddison LA; Wei Y; DeMayo F; Petras T; Li B; Gingrich JR; Rosen JM; Greenberg NM
Mol Cancer Res; 2003 Dec; 1(14):1036-47. PubMed ID: 14707287
[TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas.
Skomedal H; Kristensen GB; Lie AK; Holm R
Gynecol Oncol; 1999 May; 73(2):223-8. PubMed ID: 10329038
[TBL] [Abstract][Full Text] [Related]
15. Polycyclic aromatic hydrocarbon carcinogens increase ubiquitination of p21 protein after the stabilization of p53 and the expression of p21.
Nakanishi Y; Pei XH; Takayama K; Bai F; Izumi M; Kimotsuki K; Inoue K; Minami T; Wataya H; Hara N
Am J Respir Cell Mol Biol; 2000 Jun; 22(6):747-54. PubMed ID: 10837373
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of MDM-2 mRNA and mutation of the p53 tumor suppressor gene in bladder carcinoma cell lines.
Cheng YT; Li YL; Wu JD; Long SB; Tzai TS; Tzeng CC; Lai MD
Mol Carcinog; 1995 Jul; 13(3):173-81. PubMed ID: 7619220
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional inactivation of p53, Bax, Bcl-2 and Mdm2 correlates with malignant transformation of the uterine cervix.
Soufla G; Baritaki S; Sifakis S; Zafiropoulos A; Spandidos DA
Int J Biol Markers; 2005; 20(1):18-27. PubMed ID: 15832769
[TBL] [Abstract][Full Text] [Related]
18. [Genic alterations in oral and head and neck squamous cell carcinomas: analysis of international literature].
Raybaud H; Odin G; Fafet A; Santini J; Monteil RA
Pathol Biol (Paris); 2003 Apr; 51(3):176-84. PubMed ID: 12781800
[TBL] [Abstract][Full Text] [Related]
19. Diversity of the apoptotic response to chemotherapy in childhood leukemia.
Liu T; Raetz E; Moos PJ; Perkins SL; Bruggers CS; Smith F; Carroll WL
Leukemia; 2002 Feb; 16(2):223-32. PubMed ID: 11840289
[TBL] [Abstract][Full Text] [Related]
20. Expression patterns of the p53 tumor suppressor gene and the mdm2 proto-oncogene in human meningiomas.
Pykett MJ; Landers J; George DL
J Neurooncol; 1997 Mar; 32(1):39-44. PubMed ID: 9049861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
